[{"id":"fe61047d-8ed4-4b77-a9be-8df7e1bcb409","acronym":"","url":"https://clinicaltrials.gov/study/NCT06040541","created_at":"2023-09-15T18:10:24.393Z","updated_at":"2024-07-02T16:35:21.224Z","phase":"Phase 1","brief_title":"Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors","source_id_and_acronym":"NCT06040541","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zoldonrasib (RMC-9805)"],"overall_status":"Recruiting","enrollment":" Enrollment 290","initiation":"Initiation: 09/07/2023","start_date":" 09/07/2023","primary_txt":" Primary completion: 08/30/2025","primary_completion_date":" 08/30/2025","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-02-01"}]